Guangli Suo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Guangli Suo has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Yong Qiao
Nanjing LivingChip Biotechnology Co., Ltd, Nanjing, China
9 shared publicationsZhongjuan Xu
CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China
8 shared publicationsYanzhen Yu
CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China
7 shared publicationsHong Qiao
Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
6 shared publicationsTongqian Xiao
CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Jiangsu, 215123, China; University of Chinese Academy of Sciences, Beijing, 100049, China
6 shared publicationsJunsa Geng
Chinese Acad Sci, Suzhou Inst Nanotech & Nanobion, CAS Key Lab Nanobio Interface, Suzhou 215123, Peoples R China
5 shared publications
Latest Publications
- 13 May 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (6) , 1328-1342
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform
Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.
- 13 May 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (6) , 1328-1342
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform
Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.
- Open Access
- 6 March 2026
- Published by Springer Nature
Cellular morphology assay of M231 by Giemsa staining v1
The cellular morphology of M231 and MTS-M231 cells in monolayer culture was assessed using the Giemsa staining assay. Briefly, a total of 50,000 cells were seeded in each well of a 6-well plate and cultured for 3 days in complete medium. Subsequently, the cells were fixed with 70% ethanol for 10 minutes and stained with Giemsa dye (Beyotime) for 30 minutes. The nuclei were stained with a purplish-red color, while the cytoplasm exhibited a blue hue. The images were captured using a phase contrast microscope (Scope A1, Zeiss).
- 6 March 2026
- Published by Springer Nature
Open AccessCellular morphology assay of M231 by Giemsa staining v1
The cellular morphology of M231 and MTS-M231 cells in monolayer culture was assessed using the Giemsa staining assay. Briefly, a total of 50,000 cells were seeded in each well of a 6-well plate and cultured for 3 days in complete medium. Subsequently, the cells were fixed with 70% ethanol for 10 minutes and stained with Giemsa dye (Beyotime) for 30 minutes. The nuclei were stained with a purplish-red color, while the cytoplasm exhibited a blue hue. The images were captured using a phase contrast microscope (Scope A1, Zeiss).
- Open Access
- 6 March 2026
- Published by Springer Nature
Comparison of drug sensitivity between MTSs and their parental cells v1
Cell viability was assessed using the CellTiter-Glo (CTG) assay to quantify drug-induced changes in cellular metabolic activity.
- 6 March 2026
- Published by Springer Nature
Open AccessComparison of drug sensitivity between MTSs and their parental cells v1
Cell viability was assessed using the CellTiter-Glo (CTG) assay to quantify drug-induced changes in cellular metabolic activity.
- Open Access
- 6 March 2026
- Published by Springer Nature
Generation and collection of MTSs v1
The definition of MFR and the collection of MTS。
- 6 March 2026
- Published by Springer Nature
Open AccessGeneration and collection of MTSs v1
The definition of MFR and the collection of MTS。
- Open Access
- 13 February 2026
- Published by Springer Nature
H&E and Immunohistochemistry (IHC) Staining v1
H&E and Immunohistochemistry (IHC) Staining for MTS and BRC tissue.
- 13 February 2026
- Published by Springer Nature
Open AccessH&E and Immunohistochemistry (IHC) Staining v1
H&E and Immunohistochemistry (IHC) Staining for MTS and BRC tissue.
- Open Access
- 13 February 2026
- Published by Springer Nature
Cell apoptosis assay v1
Quantitative assessment of apoptotic cell populations by flow cytometry using fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium iodide (PI) dual staining.
- 13 February 2026
- Published by Springer Nature
Open AccessCell apoptosis assay v1
Quantitative assessment of apoptotic cell populations by flow cytometry using fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium iodide (PI) dual staining.
- Open Access
- 13 February 2026
- Published by Springer Nature
In vitro LDTIA of tumors based on MTS formation v1
A in vitro model for determining the proportion of CSCs in clinical BRC tissue.
- 13 February 2026
- Published by Springer Nature
Open AccessIn vitro LDTIA of tumors based on MTS formation v1
A in vitro model for determining the proportion of CSCs in clinical BRC tissue.
- Open Access
- 13 February 2026
- Published by Springer Nature
Cell proliferation related assays v1
Clonogenic survival assay in soft agar and Matrigel and cell proliferation assay of MTS-M231 cells
- 13 February 2026
- Published by Springer Nature
Open AccessCell proliferation related assays v1
Clonogenic survival assay in soft agar and Matrigel and cell proliferation assay of MTS-M231 cells
- Open Access
- 13 February 2026
- Published by Springer Nature
Western blot v1
The protein levels of BRC tissue and MTSs was detected via western blot.
- 13 February 2026
- Published by Springer Nature
Open AccessWestern blot v1
The protein levels of BRC tissue and MTSs was detected via western blot.
- Open Access
- 13 February 2026
- Published by Springer Nature
Determination of the cutoff value for drug efficacy in MTSs model v1
Determination of clinical drug concentrations in the MTS model to predict patient-relevant chemotherapeutic response.
- 13 February 2026
- Published by Springer Nature
Open AccessDetermination of the cutoff value for drug efficacy in MTSs model v1
Determination of clinical drug concentrations in the MTS model to predict patient-relevant chemotherapeutic response.